JACC Journals

Mark your calendars for the annual #JACCJournals Reception at #ACC25! ?? Sunday, 3/30 ?? 5:30 PM CT ?? Marriot Marquis, Level 4, Grand Horizon EF Join Journal Editors to network and celebrate groundbreaking research across the journals. RSVP now to save your spot: https://lnkd.in/ei4aZzJn

Treatment of severe heart failure (HF) across the spectrum of #LVEF with the SGLT2 inihbitor #dapagliflozin appeared to be safe and effective in reducing the risk of cardiovascular death or worsening HF, according to an analysis of results from the DAPA-HF and DELIVER clinical trials published in #JACCHF: https://bit.ly/3DPj7cW #CVD #SGLT2i #HeartFailure

#JACCCardioOnc values education, research and advocacy in advancing #amyloidosis care. Explore our Amyloidosis Hub this #AmyloidosisAwarenessMonth for original research, case challenges, videos, podcasts and more! https://bit.ly/3Fb0dOb

A #JACCIMG state-of-the-art review summarizes a discussion by the #Amyloidosis Forum on the role of imaging biomarkers as trial endpoints in the diagnosis and assessment of systemic immunoglobin light chain (AL) and transthyretin (#ATTR) amyloidosis. Get the details: https://bit.ly/4ij9CBT

A new #JACCAdvances paper compares the quality of cardiovascular care in Veterans Healthcare Administration (VHA) vs. community care - care delivered outside VHA by non-VHA providers but authorized and funded by VHA. The study examines quality metrics and highlights innovative national care programs. Get the details: https://bit.ly/3FlJ7Nu

A recent State-of-the-Art Review published in #JACCHF provides evidence-based recommendations on how to best optimize the care of patients with heart failure through non-pharmacological strategies, including diet, exercise and cardiac rehabilitation, as well as addressing sleep-disordered breathing, mood disorders and substance use disorders. https://bit.ly/4ksQumr

?? #JACCCaseReports Call for Papers: Multi-Valve Disease (MVD) In partnership with the Heart Valve Collaboratory, this issue will feature your work alongside expert editorials, offering contemporary insights into MVD management, treatment strategies, and future directions. Learn more and submit: https://bit.ly/4fFiEqJ Gilbert Tang, MD, MSc, MBA, FRCSC, FACC, FSCAI Minnow Walsh Dee Dee Wang, MD, FACC, FASE, FSCCT, FSCAI

A State-of-the-Art Review published in #JACCBTS highlights the potential of emerging thrombolytic therapies such as antagonists of fibrinolysis inhibitors to improve safety and efficacy of the treatment and prevention of acute thrombosis in patients with venous thromboembolism. Get the details: https://lnkd.in/eE3VmHDW #VTE

The definition of a high-risk plaque should be expanded beyond the traditional focus on plaque rupture and thin-cap fibroatheroma in the setting of acute coronary syndromes, according to a new #JACCIMG Position Statement. In the Statement, authors Rocco Vergallo, MD, et al., write that the concept of the high-risk plaque is affected by evolving cardiovascular risk and advances in pharmacotherapy. Thus, its definition "must broadly encompass all lesion precursors that are thrombosis prone," such as plaque rupture, plaque erosion and eruptive calcified nodules. https://bit.ly/3F2V0b3 #cvACS

The 2025 ACC/AHA/SCAI ACS guidelines are here! Lowering LDL beyond <70 mg/dL to a target of 55 mg/dL in secondary prevention is now strongly recommended???? If the patient is on the maximum statin dose, intensify lipid-lowering therapy further?? American College of Cardiology JACC Journals https://lnkd.in/gbQ2FniN